Press Releases :: Aurinia Pharmaceuticals Inc. (AUPH)

March 19, 2019 • 4:02 pm EDT

Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights

March 14, 2019 • 7:00 am EDT

Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease

March 7, 2019 • 4:05 pm EST

Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019

February 27, 2019 • 6:30 am EST

Aurinia Closes At-The-Market Facility

February 25, 2019 • 7:00 am EST

Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis

February 20, 2019 • 4:01 pm EST

Aurinia to Present at the 8th Annual SVB Leerink Global Healthcare Conference New York City

January 22, 2019 • 7:00 am EST

Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome

January 21, 2019 • 4:49 pm EST

Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome

Select a page:

rss_feed News RSS

©2025 Aurinia Pharmaceuticals Inc. All Rights Reserved. US-LUP-2300105 08/23